机构：[1]State Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences &[2] Peking Union Medical College, Suzhou, China.[2]4+4 Medical Doctor Program, Chinese Academy of Medical Sciences &[4] Peking Union Medical College, Beijing, China.[3]Beijing Cloudna Technology Co., Ltd., Beijing, China.[4]School of Biological Sciences, Sichuan University, Chengdu, China.[5]Beijing Key Laboratory for Genetics of Birth Defects, Beijing Pediatric Research Institute, MOE Key Laboratory of Major Diseases in Children首都医科大学附属北京儿童医院[8] Rare Disease Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.首都医科大学附属北京儿童医院[6]Guangzhou National Laboratory, Guangzhou, China.
第一作者机构：[1]State Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences &
通讯作者：
推荐引用方式(GB/T 7714)：
Wan Zhaoman,Jiang Nan,Su Mingming,et al.Multiscale fusion network drives the repurposing of anticancer drugs[J].CLINICAL AND TRANSLATIONAL MEDICINE.2024,14(7):e1745.doi:10.1002/ctm2.1745.
APA：
Wan Zhaoman,Jiang Nan,Su Mingming,Zhang Xinlei,Cao Yang...&Jiang Taijiao.(2024).Multiscale fusion network drives the repurposing of anticancer drugs.CLINICAL AND TRANSLATIONAL MEDICINE,14,(7)
MLA：
Wan Zhaoman,et al."Multiscale fusion network drives the repurposing of anticancer drugs".CLINICAL AND TRANSLATIONAL MEDICINE 14..7(2024):e1745
